Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial Using a Proprietary Cannabis-based Medicine for the Treatment of the Symptoms of Neurodegenerative Diseases
BENSHEIM, Germany, Oct. 08, 2024 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading European manufacturer and developer of Cannabis-based medicines located in Germany, is proud to announce that both the Italian Medicines Agency AIFA and th…
- The Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for NEUROBIS; a multi-centre Phase II study to evaluate safety, and efficacy of an Avextra or…